Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:002294)

Market Cap	50.87B +48.2%
Revenue (ttm)	4.25B +8.8%
Net Income	672.56M +10.1%
EPS	0.60 +9.2%
Shares Out	1.11B
PE Ratio	76.02
Forward PE	75.80
Dividend	0.50 (1.07%)
Ex-Dividend Date	May 14, 2025

Volume	6,299,062
Average Volume	8,001,972
Open	47.33
Previous Close	45.63
Day's Range	44.95 - 47.33
52-Week Range	27.66 - 65.63
Beta	0.61
RSI	26.33
Earnings Date	Mar 24, 2026

About SHE:002294

Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also develops Sacubitril Allisartan Calcium, Allisartan Isoproxil Amlodipine Besylate Tablets, and Allisartan IsoproxilIndapamide Sustained-release Tablets, which are in ph...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 3,596
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002294

Financial Performance

In 2024, SHE:002294's revenue was 4.01 billion, an increase of 19.22% compared to the previous year's 3.37 billion. Earnings were 601.57 million, an increase of 3.71%.